These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 30136337

  • 1. The effect of a multispecies probiotic on microbiota composition in a clinical trial of patients with diarrhea-predominant irritable bowel syndrome.
    Hod K, Dekel R, Aviv Cohen N, Sperber A, Ron Y, Boaz M, Berliner S, Maharshak N.
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13456. PubMed ID: 30136337
    [Abstract] [Full Text] [Related]

  • 2. A double-blind, placebo-controlled study to assess the effect of a probiotic mixture on symptoms and inflammatory markers in women with diarrhea-predominant IBS.
    Hod K, Sperber AD, Ron Y, Boaz M, Dickman R, Berliner S, Halpern Z, Maharshak N, Dekel R.
    Neurogastroenterol Motil; 2017 Jul; 29(7):. PubMed ID: 28271623
    [Abstract] [Full Text] [Related]

  • 3. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B, Mun Jung S, Hwan Choi C, Song ID, Woong Lee H, Joon Kim H, Hyuk J, Kyung Chang S, Kim K, Chung WS, Seo JG.
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [Abstract] [Full Text] [Related]

  • 4. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM, Khosruzzaman SM, Ahmed DS, Sah MP.
    BMC Gastroenterol; 2018 May 25; 18(1):71. PubMed ID: 29801486
    [Abstract] [Full Text] [Related]

  • 5. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG.
    J Gastroenterol Hepatol; 2014 Jan 25; 29(1):52-9. PubMed ID: 23829297
    [Abstract] [Full Text] [Related]

  • 6. The effect of Clostridium butyricum on symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Sun YY, Li M, Li YY, Li LX, Zhai WZ, Wang P, Yang XX, Gu X, Song LJ, Li Z, Zuo XL, Li YQ.
    Sci Rep; 2018 Feb 14; 8(1):2964. PubMed ID: 29445178
    [Abstract] [Full Text] [Related]

  • 7. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
    Maharshak N, Ringel Y, Katibian D, Lundqvist A, Sartor RB, Carroll IM, Ringel-Kulka T.
    Dig Dis Sci; 2018 Jul 14; 63(7):1890-1899. PubMed ID: 29777439
    [Abstract] [Full Text] [Related]

  • 8. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T, Zeng H, Long Y, Li X, Sun X, Lan Y, Gao L, Zhang L, Feng Z, Hou X.
    Trials; 2020 Jun 30; 21(1):597. PubMed ID: 32605578
    [Abstract] [Full Text] [Related]

  • 9. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kanarek E, Sowińska A, Cukrowska B.
    Nutrients; 2021 Feb 26; 13(3):. PubMed ID: 33652763
    [Abstract] [Full Text] [Related]

  • 10. Probiotics Ameliorate Stool Consistency in Patients with Chronic Constipation: A Randomized, Double-Blind, Placebo-Controlled Study.
    Yoon JY, Cha JM, Oh JK, Tan PL, Kim SH, Kwak MS, Jeon JW, Shin HP.
    Dig Dis Sci; 2018 Oct 26; 63(10):2754-2764. PubMed ID: 29876777
    [Abstract] [Full Text] [Related]

  • 11. The Effectiveness of Synbiotic Preparation Containing Lactobacillus and Bifidobacterium Probiotic Strains and Short Chain Fructooligosaccharides in Patients with Diarrhea Predominant Irritable Bowel Syndrome-A Randomized Double-Blind, Placebo-Controlled Study.
    Skrzydło-Radomańska B, Prozorow-Król B, Cichoż-Lach H, Majsiak E, Bierła JB, Kosikowski W, Szczerbiński M, Gantzel J, Cukrowska B.
    Nutrients; 2020 Jul 05; 12(7):. PubMed ID: 32635661
    [Abstract] [Full Text] [Related]

  • 12. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome.
    Pinto-Sanchez MI, Hall GB, Ghajar K, Nardelli A, Bolino C, Lau JT, Martin FP, Cominetti O, Welsh C, Rieder A, Traynor J, Gregory C, De Palma G, Pigrau M, Ford AC, Macri J, Berger B, Bergonzelli G, Surette MG, Collins SM, Moayyedi P, Bercik P.
    Gastroenterology; 2017 Aug 05; 153(2):448-459.e8. PubMed ID: 28483500
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and dose response of Lactiplantibacillus plantarum in diarrhea-predominant irritable bowel syndrome.
    Martoni CJ, Srivastava S, Damholt A, Leyer GJ.
    World J Gastroenterol; 2023 Jul 28; 29(28):4451-4465. PubMed ID: 37576702
    [Abstract] [Full Text] [Related]

  • 14. Baseline gut microbial profiles are associated with the efficacy of Bacillus subtilis and Enterococcus faecium in IBS-D.
    Hong G, Li Y, Yang M, Li G, Jin Y, Xiong H, Qian W, Hou X.
    Scand J Gastroenterol; 2023 Apr 28; 58(4):339-348. PubMed ID: 36281578
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of purified clinoptilolite-tuff treatment in patients with irritable bowel syndrome with diarrhea: Randomized controlled trial.
    Anderle K, Wolzt M, Moser G, Keip B, Peter J, Meisslitzer C, Gouya G, Freissmuth M, Tschegg C.
    World J Gastroenterol; 2022 Dec 14; 28(46):6573-6588. PubMed ID: 36569277
    [Abstract] [Full Text] [Related]

  • 16. Involvement of shared mucosal-associated microbiota in the duodenum and rectum in diarrhea-predominant irritable bowel syndrome.
    Li G, Yang M, Jin Y, Li Y, Qian W, Xiong H, Song J, Hou X.
    J Gastroenterol Hepatol; 2018 Jun 14; 33(6):1220-1226. PubMed ID: 29194775
    [Abstract] [Full Text] [Related]

  • 17. Clinical and Microbiological Effect of a Multispecies Probiotic Supplementation in Celiac Patients With Persistent IBS-type Symptoms: A Randomized, Double-Blind, Placebo-controlled, Multicenter Trial.
    Francavilla R, Piccolo M, Francavilla A, Polimeno L, Semeraro F, Cristofori F, Castellaneta S, Barone M, Indrio F, Gobbetti M, De Angelis M.
    J Clin Gastroenterol; 2019 Mar 14; 53(3):e117-e125. PubMed ID: 29688915
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial.
    Han K, Wang J, Seo JG, Kim H.
    J Gastroenterol; 2017 Apr 14; 52(4):432-443. PubMed ID: 27178566
    [Abstract] [Full Text] [Related]

  • 19. Clinical response to fecal microbiota transplantation in patients with diarrhea-predominant irritable bowel syndrome is associated with normalization of fecal microbiota composition and short-chain fatty acid levels.
    Mazzawi T, Hausken T, Hov JR, Valeur J, Sangnes DA, El-Salhy M, Gilja OH, Hatlebakk JG, Lied GA.
    Scand J Gastroenterol; 2019 Jun 14; 54(6):690-699. PubMed ID: 31190584
    [Abstract] [Full Text] [Related]

  • 20. A double-blind, randomized, placebo-controlled study assessing the impact of probiotic supplementation on the symptoms of irritable bowel syndrome in females.
    Mullish BH, Michael DR, Dabcheva M, Webberley TS, Coates N, John DA, Wang D, Luo Y, Plummer SF, Marchesi JR.
    Neurogastroenterol Motil; 2024 Apr 14; 36(4):e14751. PubMed ID: 38287443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.